Mode
Text Size
Log in / Sign up
N/A Completed N=1,841

Additional Effect of A Life Style Program on Antihypertensive Treatment With Telmisartan

Source: ClinicalTrials.gov NCT01108796 ↗
Enrolled (actual)
1,841
Serious AEs
0.1%
Results posted
Dec 2011
Primary outcomePrimary: Changes in Mean Blood Pressure (Systolic) After Treatment, Compared to Baseline — -30.71; -30.32; -30.35; -30.73 mmHg

Summary

This post-marketing surveillance study is designed to supplement the data on efficacy and tolerability of Micardis® and MicardisPlus® in patients at cardiovascular risk under general practice conditions. The aim of the study is to investigate the effect of a six-month treatment with Micardis® / MicardisPlus® on blood pressure and the effect of the Lifestyle education tool for weight reduction on blood pressure control. In addition, the post-marketing surveillance study will provide information on the effects on target measurement of the Lifestyle education tool and various laboratory parameters produced by treatment with Micardis® and MicardisPlus® in an unselected patient population under general practice conditions.

Outcome Measures

OutcomeResultp-value
PRIMARY
Changes in Mean Blood Pressure (Systolic) After Treatment, Compared to Baseline
-30.71; -30.32; -30.35; -30.73 —
PRIMARY
Changes in Mean Blood Pressure (Diastolic) After Treatment, Compared to Baseline
-14.73; -15.31; -15.29; -14.65 —
SECONDARY
Changes in Laboratory Parameters:Low Density Lipoprotein (LDL)
-0.41; -0.51; -0.50; -0.40 —
SECONDARY
Changes in Laboratory Parameters:High Density Lipoprotein (HDL)
0.11; 0.09; 0.12; 0.06 —
SECONDARY
Changes in Laboratory Parameters: Triglycerides
-0.24; -0.30; -0.32; -0.18 —
SECONDARY
Changes in Laboratory Parameters: Blood Glucose
-0.49; -0.45; -0.49; -0.42 —
SECONDARY
Assessment of Metabolic Effect
544; 695; 835; 404; 222; 361 —

Eligibility Criteria

Inclusion criteria

  • Patients with essential hypertension (blood pressure (BP) higher or equal to 140/90 mmHg or higher or equal to 130/80 mmHg in case of diabetic patients)
  • Patients with hypertension under treatment with one or more antihypertensive drug

Exclusion criteria

Patients are excluded according to the summary of product characteristics (SmPC).

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01108796). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search